Author Archives: ev1

Clinical Laboratory Services Market is Expected to Reach USD 241.37 Billion Globally in 2019: Transparency Market …

Posted on by

ALBANY, New York, October 3, 2013 /PRNewswire/ --

According to a new market report published by Transparency Market Research "Clinical Laboratory Services Market (Clinical Chemistry, Medical Microbiology & Cytology, Human & Tumor Genetics and Other Esoteric Tests) -Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global clinical laboratory services market was valued at USD 162.71 billion in 2012 and is expected to grow at a CAGR of 5.8% from 2013 to 2019, to reach an estimated value of USD 241.37 billion in 2019.

Browse the full report with complete TOC athttp://www.transparencymarketresearch.com/clinical-laboratory-services-market.html

Clinical laboratories refer to the centers for conducting diagnostic testing and related services to identify disease causes, level of progression (stage) of the disease, resultant abnormalities and imbalances in the physiology, and other such factors. Along with processing samples and generating patient reports, players in this market also offer informatics solutions which help in effective data management for the large volume of tests ordered and performed each day. The global market for clinical laboratory services is expected to grow at a CAGR of 5.8% during the forecast period due to the increasing incidence rates of diseases worldwide along with the introduction of newer and sophisticated diagnostic tests.

The market for clinical laboratory services has been segmented by different categories of tests performed such as clinical chemistry, genetic tests, medical microbiology & cytology tests and other esoteric tests. The market for medical microbiology & cytology tests is expected to grow at the highest CAGR of 7.1% during the forecast period due to the increasing burden of infectious diseases globally, that demands large testing volume capacities from clinical laboratories. Although core laboratory tests, which constitute the clinical chemistry market segment, are basic tests extensively conducted across patient populations, this market segment is expected to witness mediocre growth at a CAGR of 5.3%. This is due to the limited scope for innovation in this market in terms of developing newer tests and the growing importance of informatics solutions in the same.

On the basis of geographic regions, this market was studied with reference to North America, Europe, Asia-Pacific and Rest of the World. North America and Asia-Pacific regions are expected to emerge as highly attractive markets for clinical laboratory services in the future, in terms of market revenue and growth respectively. The market is divided into three major types of service providers- clinic-based, hospital-based and stand-alone laboratories. Of these, hospital-based laboratories generate the maximum revenue globally are expected to continue to do so during the forecast period.

The market for clinical laboratory services is fragmented, with Quest Diagnostics, Inc. (U.S.) and Laboratory Corporation of America Holdings (U.S.) dominating the market in terms of revenue generation. Some of the other key players include Sonic Healthcare (Australia), Genoptix Medical Laboratory (U.S.), Labco S.A. (France), Healthscope Ltd. (Australia), Bio-Reference Laboratories (U.S.), and Bioscientia Healthcare (Germany).

Related & Recently Published Reports by Transparency Market Research

The global clinical laboratory services market is segmented as follows:

Clinical Laboratory Services Market, by Test Type

Read the original here:
Clinical Laboratory Services Market is Expected to Reach USD 241.37 Billion Globally in 2019: Transparency Market ...

Resveratrol, Compound In Red Wine, Could Be Beneficial After All

Posted on by

By Tia Ghose, Staff Writer Published: 10/02/2013 02:53 PM EDT on LiveScience

Resveratrol, a chemical found in red wine that is often touted for its anti-aging benefits, is chemically active in cells, which has been doubted, according to new research.

Despite earlier research on resveratrol's activity in the human body that cast doubt on its potential to benefit people's health, the new findings show the compound can be converted in the body into its active form, which cells can use.

That conclusion, published today (Oct. 2) in the journal Science Translational Medicine, bolsters the notion that the compound could have health benefits. [4 Foods That Are Good Sources of Resveratrol]

Red wine compound

Resveratrol is found in the skin of red grapes, dark chocolate and other foods, and many believe it has potential health benefits. Some research has found that the compound can activate a chemical pathway in cells linked to slower aging, and other studies have tied it to cardiovascular benefits and anti-cancer effects.

However, studies of the compound in people and animals have yielded mixed results. One found that resveratrol extends the life span of fat mice, but has no benefit for their lean counterparts. And a 2012 study in Cell Metabolism found that healthy people taking resveratrol supplements gained no benefit from them.

In addition, researchers weren't sure how resveratrol could be active biologically.

"One of the major problems is that when you eat it, it's very, very quickly converted by the body into sulfate and gluconoride metabolites," said study co-author Karen Brown, a cancer researcher at the University of Leicester in England.

Some scientists doubted that resveratrol sulfate, the modified form of the chemical, was active in the body.

Link:
Resveratrol, Compound In Red Wine, Could Be Beneficial After All

Durata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro …

Posted on by

SAN FRANCISCO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (DRTX) today announced a comprehensive review of the efficacy, safety and microbiology data of the company's lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). The data is being presented in six posters at this year's IDWeek 2013(TM), held in San Francisco, Calif., October 2-6, 2013. Among the findings, an integrated analysis of two Phase 3 clinical studies (DISCOVER 1 and 2) showed dalbavancin met its primary and secondary endpoints of early response, measured at 48 to 72 hours of therapy, as well as clinical success at the end of treatment. Sensitivity analyses for both timepoints were also included.i A separate analysis showed that patients achieving cessation of spread of the lesion after 72 hours of antibiotic treatment with dalbavancin have a greater than 90 percent chance of being cured at the end of treatment.ii A pooled summary analysis of the safety profile of dalbavancin based on the Phase 2 and 3 clinical program also found it to be generally well-tolerated and to have a similar safety profile to comparators with fewer adverse events.iii Examination of patients with baseline Gram-positive bacteremia enrolled in the dalbavancin clinical development program as well as in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA) and Neisseria gonorrhoeae were also presented.

"The data show that dalbavancin has the potential to be an efficacious and well-tolerated treatment option for patients with ABSSSI," said Durata Therapeutics Chief Medical Officer Michael Dunne, M.D. "Our studies were designed to meet the new standards required by regulatory authorities for antibiotic development in the United States and European Union and support our New Drug Application submission to the Food and Drug Administration late last week."

Dalbavancin is a novel antibacterial under investigation for the treatment of ABSSSI caused by susceptible Gram-positive microorganisms, such as S. aureus (including MRSA and other multi-drug resistant strains) and Streptococcus pyogenes, as well as certain other streptococcal species. Dalbavancin is bactericidal against Gram-positive bacteria and is administered with a once-weekly dosage regimen of 1000 mg on Day 1 and 500 mg on Day 8, over 30 minutes by intravenous infusion.

Copies of the following posters will be available on Durata Therapeutics' website: http://www.duratatherapeutics.com.

Poster # 1339: An Integrated Analysis of the Efficacy of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the DISCOVER Programi (Date: October 5, 2013)

Data were presented from an integrated analysis of the efficacy results from the DISCOVER ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") program and found that dalbavancin is non-inferior to the comparator regimen at both an early timepoint and at the end of therapy. The DISCOVER program includes two Phase 3 identically designed multicenter, double-blind, randomized clinical trials of more than 1,300 adult patients with ABSSSI from the United States, Europe, Asia and South Africa. Patients were treated for two weeks either with intravenous dalbavancin once weekly (1000 mg on Day 1 followed by 500 mg on Day 8) or with intravenous vancomycin (1000 mg or 15 mg/kg every 12 hours) with the option to switch to oral linezolid after three days. Primary endpoints from the DISCOVER trials were cessation of spread of the erythema associated with the lesion and resolution of fever measured at 48-72 hours per FDA requirements. While a secondary endpoint for FDA, clinical success at end of treatment is the expected primary endpoint for regulatory review in Europe. Examining both endpoints provides clinicians with correlation between the early and late findings.

The integrated efficacy analysis found that:

Poster # 1340: Concordance of Clinical Response at 48-72 Hours after Initiation of Therapy and End of Treatment (EOT) in Patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in the DISCOVER Studiesii (Date: October 5, 2013)

An additional analysis of the DISCOVER clinical trials examined the concordance of study endpoints (i.e., clinical response at 48-72 hours after initiation of therapy as well as at the end of treatment) and found that the majority of early responders were ultimately cured. Specifically, the analysis found that:

"The early assessment timepoint recommended by the FDA was put in place to guide antibiotic drug development for ABSSSI," said Mark Wilcox, M.D., Head of Microbiology, Leeds Teaching Hospitals and Professor of Medical Microbiology at the University of Leeds, UK and an advisor to the DISCOVER clinical trial program. "These data, however, may also give physicians confidence at an early timepoint that could help identify patients who could ultimately be cured and those who might fail."

Read the rest here:
Durata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro ...

Southern California Stem Cell Therapy Clinic, TeleHealth, Now Offering Stem Cells for Knee Arthritis

Posted on by

Orange, CA (PRWEB) September 30, 2013

TeleHealth, the leading stem cell therapy clinic on the West Coast, is now offering multiple treatments with stem cells for knee arthritis. The stem cell treatments are very exciting as they present the possibility of repairing and regenerating arthritis damage in the knees. The treatments are offered by Board Certified stem cell doctors at the clinic in outpatient, low risk procedures that are often covered by insurance. Call (888) 828-4575 for more information and scheduling.

Over the past few years, increasing studies are showing the benefits of regenerative medicine treatments for knee arthritis. This includes a study out of the Hospital for Special Surgery last year showing effectiveness of platelet rich plasma therapy for knee arthritis. Treatment options at TeleHealth include both platelet rich plasma therapy (PRP therapy) along with bone marrow derived stem cell injection therapy or fat derived stem cell therapy.

Often, the treatments are combined to produce maximum knee arthritis benefit and allow patients to avoid surgery, reduce pain and dramatically increase functional ability. While knee replacement surgery has been shown to have a high success rate, the components are not meant to last forever and there can be complications with the surgery.

Therefore, it makes sense to try conservative treatment prior such as with the regenerative medicine options at TeleHealth. Especially considering the stem cell treatments are often covered by insurance.

TeleHealths main stem cell clinic is located in Orange, CA, convenient to major freeways and not far from San Diego, Los Angeles, Santa Ana and Inland Empire. The highly skilled stem cell doctors at the clinic are Board Certified and have years of experience treating musculoskeletal conditions with stem cell treatments including shoulder arthritis, rotator cuff tendonitis, Achilles tendonitis, tennis elbow, muscle tears and much more.

Call (888) 828-4575 for more information and scheduling.

Excerpt from:
Southern California Stem Cell Therapy Clinic, TeleHealth, Now Offering Stem Cells for Knee Arthritis

In Vitro Diagnostics: World Market Outlook 2013-2023

Posted on by

NEW YORK, Sept. 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

In Vitro Diagnostics: World Market Outlook 2013-2023 http://www.reportlinker.com/p0578540/In-Vitro-Diagnostics-World-Market-Outlook-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Report Details

In vitro diagnostic tests - your guide to trends and revenue prospects

What's the future of in vitro diagnostic (IVD) testing? Visiongain's updated report predicts those revenues to 2023. There you find the best places for sales growth, also understanding trends, technologies, and opportunities.

That study gives you revenue forecasts to 2023 at overall world market, submarket, and national level. See what's happening for those technologies, finding how you can gain.

Read on to explore that industry and see what its future market could be worth.

Forecasts 2013-2023 and other analyses to help you understand IVD potential

Besides revenue forecasting to 2023, our new work shows recent results, growth rates, and market shares. There you find original analysis. See technological developments too. You also get 52 tables, 40 charts, and two interviews. Many opportunities remain for those technologies and products. Now see how you can benefit your research, analyses, and decisions for IVD, also saving time. You hear what's happening there and see where the money lies. That way you reduce your risk of missing out. Finding data you need there just got easier. Try our new report.

The following sections show, then, how you benefit from our new investigation and analysis.

See original here:
In Vitro Diagnostics: World Market Outlook 2013-2023

ANSI Seeks Organizations to Take Part in International Standards Development Work on Microbiology

Posted on by

Previous | Printer-friendly

ANSI Seeks Organizations to Take Part in International Standards Development Work on Microbiology New York September 30, 2013

All U.S. stakeholder organizations in relevant fields and industries are strongly encouraged to get involved and help influence the development of standards in this important field. Participants will have the opportunity to assist with the development of international standards on food-related microbiology that will have a significant impact on both food and animal feeds.

ISO TC 34/SC 9 is responsible for the development of International Standards on topics connected to food-related microbiology. The subcommittee is actively at work on standards, including recently approved efforts to begin development of standards on microbiological methods for the detection of Salmonella and Bacillus cereus emetic toxin in food and animal feeds, among other projects. The U.S. TAG to TC 34/SC 9 is responsible for advising ANSI on voting positions relevant to proposed and in-development standards, and carrying out detailed discussions related to these documents.

As the U.S. member body to ISO, ANSI accredits U.S. TAGs to develop and transmit U.S. positions on ISO technical activities. ANSI currently serves as the U.S. TAG Administrator to TC 34/SC 9, with financial and technical support from the U.S. Food and Drug Administration (FDA).

Organizations interested in joining the TAG or seeking to obtain additional information about TC 34/SC 9, the U.S. TAG, and related activities should email tc34sc9@ansi.org. Additional information will be provided to all those who notify ANSI that they are interested in participating on the U.S. TAG.

Read this article:
ANSI Seeks Organizations to Take Part in International Standards Development Work on Microbiology

Vacuum dust: A previously unknown disease vector

Posted on by

Public release date: 30-Sep-2013 [ | E-mail | Share ]

Contact: Garth Hogan ghogan@asmusa.org 202-942-9389 American Society for Microbiology

The aerosolized dust created by vacuums contain bacteria and mold that "could lead to adverse effects in allergic people, infants, and people with compromised immunity," according to researchers at the University of Queensland and Laval University. Their findings are published ahead of print in Applied and Environmental Microbiology.

This finding is worrying as the study found resistance genes for five common antibiotics in the sampled bacteria along with the Clostridium botulinum toxin gene. This is of particular concern as, "The dust found indoors could act as a vehicle for infant botulism infection that can have severe consequences," including sudden infant death syndrome, according to previous studies.

"Even though no quantitative data are available for antibiotic resistance gene emission while vacuuming, the observed emission rates for bacteria might suggest that the genetic content of those bacterial cells, including antibiotic resistance genes, may contribute to indoor bioaerosol exposure," explain the researchers.

Researchers used a special clean air wind tunnel to measure vacuum emissions from 21 vacuums of varying quality and age. The clean air wind tunnel enabled them to eliminate other sources of particles and bacteria, says Knibbs. "That way, we could confidently attribute the things we measured purely to the vacuum cleaner."

The results were in accord with earlier studies which have shown human skin and hair to be important sources of bacteria in floor dust and indoor airwhich can be readily resuspended and inhaled, says report co-author, Caroline Duchaine.

Knibbs hopes that other studies will follow this one, raising the profile of potential indoor sources of culprits in unsolved medical cases. The investigators conclude their report, saying that vacuum cleaners are "underrepresented in indoor aerosol and bioaerosol assessment and should be considered, especially when assessing cases of allergy, asthma, or infectious diseases without known environmental reservoirs for the pathogenic or causative microbe."

###

A copy of the manuscript can be found online at http://bit.ly/1dMhUfw. Formal publication is scheduled for the October 2013 issue of Applied and Environmental Microbiology.

Read more here:
Vacuum dust: A previously unknown disease vector

Orthobiotiki Holdings Acquires Exclusive Distribution Rights of Celergen for Greece and Cyprus

Posted on by

ATHENS, Greece, Sept. 30, 2013 /PRNewswire/ --Orthobiotiki holdings, which was established in Athens in 2006 is dedicated to the specialty of Prevention, Anti-aging and Regenerative medicine. It has a state-of-the-art medical clinic in Athens, with 30 doctors of different specialties, treating patients from all over Europe. After years of research and trial, Orthobiotiki has decided to acquire the distribution rights of Celergen for Greece and Cyprus.

In recent years, Celergen, a Swiss-manufactured food supplement, has exponentially gained recognition worldwide and is featured in renowned and premier publications such as the Robb Report.

Prominent personalities, after experiencing the multi-faceted benefits of Celergen, have come forth and endorsed it. Miss Universe 1991, Lupita Jones, Magnum Group's founder, Dion R Friedland and the former President of the European Society of Anti-aging, Professor Michael Klentze, are just some of whom have taken and been benefitted from Celergen.

Consequently, Celergen is not only the choice supplement of the professional elite but has also become the preferred supplement that anti-aging doctors, plastic surgeons and functional doctors in the United States recommend to their patients.

Click here to view the Robb Report feature.

Dr. Uzzi Reiss, world famous Anti-aging specialist from Beverly Hills: "Celergen is a remarkable tool that can help improve our well-being on multiple levels. It is the Rolls Royce of supplements for the human body."

Dr. Bruce Lowell, Lowell Health and Longevity Center, Great Neck, New York: "Having seen first-hand proof of what Celergen can do, in both myself and my patients, I now know that something remarkable is definitely going on. I think Celergen marks the beginning of a new era in how we approach rejuvenating the human body."

Orthobiotiki holdings, interest in Celergen is a testament to just how grand a scale Celergen is being embraced at. Orthobiotiki, intends to promote Celergen in the Middle East and Europe as the preferred anti-aging supplement in its new venture into Preventive and Regenerative Healthcare".

For more information about Celergen please visit Orthobiotiki.com, celergenswiss.com (official European distributor) & celergenus.com (official US distributor).

Go here to read the rest:
Orthobiotiki Holdings Acquires Exclusive Distribution Rights of Celergen for Greece and Cyprus

Stratus Media Group Enters Dermatological and Restorative Medicine Industry, Signs Merger Agreement With Two …

Posted on by

LOS ANGELES--(BUSINESS WIRE)--

Stratus Media Group, Inc. (SMDI), announced today that it plans to enter the dermatological industry with the execution of a definitive merger agreement with two related companies - Canterbury Laboratories, LLC, and Hygeia Therapeutics, Inc. Upon the closing, Stratus, which will be renamed Restorgenex Corporation, plans to create a world-class cosmeceutical and pharmaceutical company in the large and expanding field of dermatology and restorative medicine. The merger agreement was approved by the board of directors of all companies and is expected to close following the satisfaction of customary closing conditions including the completion of the audit of Canterbury and Hygeia. Upon the closing, Stratus will acquire the exclusive license for 24 patent-protected compounds from Yale University. These unique compounds address hormonal aging and are scientifically validated to improve the appearance of skin and hair. Upon the closing, Restorgenex Corporation plans to build an anti-aging skincare brand for women over forty-five.

As part of this merger and its commitment to biopharmaceuticals, the company also announced today the appointment of Sol J. Barer, Ph.D., the former chairman and CEO of Celgene who has more than 30 years of experience with publicly traded biotechnology companies, as Chairman of its Board of Directors, and Isaac Blech, a leading biotechnology entrepreneur and investor, as Vice Chairman of its Board of Directors. Both will assume these positions effective November 1, 2013.

Dr. Barer spent 18 years leading Celgene as president, COO and CEO, culminating with his tenure as Celgene's executive chairman and chairman before retiring in June 2011. Under his helm, Celgene became the third largest independent biotechnology company in the world and a member of the S&P 500 with a current market capitalization exceeding $60 billion. Dr. Barer serves on the Board of several companies including: Amicus Therapeutics, Inc. and Aegerion Pharmaceuticals, Inc., and is Chairman of the Board of Cerecor, Inc., ContraFect Corp., InspireMD, Inc., Medgenics, Inc., Edge Therapeutics, Inc., and Centrexion Corporation.

Over the past three decades, Mr. Blech has become one of the most successful private company founders and financiers in the biotechnology industry. He has been instrumental in establishing some of the world's leading biotechnology companies including Celgene Corporation, Genetic Systems Corporation, ICOS Corporation, Nova Pharmaceutical Corporation and PathoGenesis Corporation. These companies are responsible for major advances in oncology, infectious disease and cystic fibrosis. Current roles include: Founder, Vice Chairman, Cerecor, Inc., a private company developing new treatments for central nervous system disorders; Director, ContraFect Corporation, a private company developing therapies for infectious diseases; Vice Chairman, Premier Alliance Group, an energy and financial regulation consulting company; Director, Medgenics, Inc., a company with a novel approach to gene therapy; Vice Chairman, SpendSmart Payments, Inc., an innovator in e-commerce, Edge Therapeutics, Inc., a research leader in brain trauma, and Centrexion Corporation, a pain control company.

We are honored to have Dr. Barer and Mr. Blech, two highly accomplished biotechnology entrepreneurs, join our Board of Directors and help build the company into a leader in the biopharmaceutical industry, said Jerold Rubinstein, current Chairman and CEO of Stratus. Mr. Rubinstein will remain a member of the Board of Directors and serve as Chairman of the companys audit committee.

As part of the transaction, Founder and Chief Executive Officer of Canterbury Laboratories and Hygeia Therapeutics, Yael Schwartz, Ph.D., will join the Restorgenexs Board of Directors. Dr. Schwartz will also serve as President of the Canterbury and Hygeia division of the company. Dr. Schwartz has over 20 years combined experience in both drug development and academic research. Prior to founding Hygeia Therapeutics, she held positions of increasing responsibility at Sepracor where she had direct responsibility for the pharmacology content of numerous INDs and NDAs for CNS and respiratory drugs.The earlier part of her career included stints at both Parexel International and the Dana-Farber Cancer Institute where she worked on cardiovascular medications and cancer therapeutics, respectively. Over the course of her career, five of the drugs she helped to discover and develop obtained FDA approval and are currently used in clinical practice.

http://www.stratusmediagroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, projections of results, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Acts of 1933 and 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors. Although the company's management believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, performance or achievements. The company has no obligation to update these forward-looking statements.

Visit link:
Stratus Media Group Enters Dermatological and Restorative Medicine Industry, Signs Merger Agreement With Two ...

Vibrio cholerae – “Colonel Cholera’s BASE cAMP” – SketchyMicro USMLE Microbiology Review – Video

Posted on by


Vibrio cholerae - "Colonel Cholera #39;s BASE cAMP" - SketchyMicro USMLE Microbiology Review
The Sketchy group is back...and we are up to no good! We have totally revamped our videos, and are planning to launch 44 bacteria videos on our website this ...

By: SketchyMicro

Original post:
Vibrio cholerae - "Colonel Cholera's BASE cAMP" - SketchyMicro USMLE Microbiology Review - Video